Illumina said on November 10, 2025 it entered into an Underwriting Agreement with Goldman Sachs & Co. LLC and BofA Securities, Inc., as representatives of the several underwriters named therein, for the issuance and sale of $500,000,000 aggregate principal amount of its 4.750% notes due 2030.

1. 01

   Illumina said on November 10, 2025 it entered into an Underwriting Agreement with Goldman Sachs & Co. LLC and BofA Securities, Inc., as representatives of the several underwriters named therein, for the issuance and sale of $500,000,000 aggregate principal amount of its 4.750% notes due 2030.

2. 02

   The company said the offering is expected to close on November 25, 2025, subject to customary closing conditions.

3. 03

   Illumina said it expects to use the net proceeds from the offering for general corporate purposes, which may include repayment of its 5.800% notes due December 12, 2025 and the completion of the proposed acquisition of SomaLogic, Inc. and the payment of any fees and expenses related thereto.

4. 04

   The company said the Notes will be issued and sold pursuant to a Registration Statement on Form S-3 (Registration No. 333-281921) that Illumina filed with the SEC on September 4, 2024, and it filed the Underwriting Agreement as Exhibit 1.1 to this Current Report on Form 8-K.

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.